Skip to content

Treating insomnia during pregnancy improves bedtime procrastination, rumination, anxiety, and positive affect: a randomized controlled trial of cognitive-behavioral and mindfulness-based therapies for prenatal insomnia.

David A Kalmbach, Anthony N Reffi, Philip Cheng, Parisa R Kaliush, Matthew B Jennings, Heba A Afaneh, Amanda Yu, Miriam Jaziri, Christopher L Drake

SLEEP Advances 2026 DOI: 10.1093/sleepadvances/zpag050 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Secondary analysis of a randomized controlled trial Peer reviewed
Sample size 64
Population Pregnant women with clinical insomnia
Interventions Cognitive-behavioral therapy for insomnia (CBTI) Perinatal Understanding of Mindful Awareness for Sleep (PUMAS) Sleep hygiene education
Measures Bedtime Procrastination Scale (BPS), Daytime Insomnia Symptom Response Scale, Generalized Anxiety Disorder-7 (GAD-7), Positive and Negative Affect Schedule, Expanded Form-Modified (PANAS), Five Facet Mindfulness Questionnaire (FFMQ)
Topics Meditation Anxiety
Keywords Cbti Pumas Cognitive arousal Maternal Rumination Sleep
Registration NCT04445805
Key findings CBTI and PUMAS produced large reductions in bedtime procrastination (Cohen's ds ≥ 1.02) and medium-to-large increases in positive affect (Cohen's ds ≥ .60). In a subsample with anxiety symptoms, both produced large anxiolytic effects (Cohen's ds ≥ .92). PUMAS reduced insomnia-focused rumination relative to sleep hygiene education (Cohen's d = .71), whereas CBTI did not. No significant effects on negative affect or mindfulness were observed.

Abstract

Insomnia is common in pregnancy and is associated with maladaptive sleep behaviors and poor emotion regulation. Cognitive-behavioral therapy for insomnia (CBTI) and Perinatal Understanding of Mindful Awareness for Sleep (PUMAS) are effective interventions for alleviating prenatal insomnia. However, clinical benefits outside the primary target of sleep remain unclear. This randomized controlled trial (RCT) explored the effectiveness of CBTI and PUMAS on bedtime procrastination, insomnia-focused rumination, anxiety, affect, and mindfulness. Secondary analysis of a single-site, three-arm RCT of N = 64 pregnant women with clinical insomnia who were randomized to CBTI, PUMAS, or sleep hygiene education (SHE). Outcomes included the bedtime procrastination scale (BPS), daytime insomnia symptom response scale, generalized anxiety disorder-7, positive and negative affect schedule, expanded form-modified (PANAS positive and negative affect), and five facet mindfulness questionnaire (FFMQ). Patients provided treatment feedback. CBTI and PUMAS were associated with large reductions in BPS (Cohen's ds ≥ 1.02) and medium-to-large effects on PANAS positive affect (Cohen's ds ≥ .60). In a subsample of patients with anxiety symptoms, CBTI and PUMAS produced large anxiolytic effects (Cohen's ds ≥ .92). PUMAS reduced insomnia-focused rumination relative to SHE (Cohen's d = .71), whereas CBTI did not. We observed no significant effects on negative affect or FFMQ. Patients identified behavioral sleep strategies, meditation, and honoring pregnancy as particularly helpful. CBTI and PUMAS yield clinical gains beyond the primary target of insomnia. These findings highlight the benefits of improving sleep quality for the betterment of overall maternal wellbeing, thereby strengthening consideration of CBTI and PUMAS as first-line treatments for prenatal insomnia. Improving Negative Stressful Perseverations in Insomnia to Revitalize Expectant Moms (INSPIRE). https://clinicaltrials.gov/study/NCT04445805, National Library of Medicine ClinicalTrials.gov Registry: NCT04445805.

Comparable studies

Other randomized controlled trials on anxiety, most cited first.

Study Year Design Participants
Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. Recovered recurrently depressed patients 2000 Randomized controlled trial n = 145
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety 2016 Randomized controlled trial n = 51
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Patients with cancer-related anxiety and depression 2016 Double-blind, placebo-controlled, crossover trial n = 29
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Hallucinogen-naïve adults reporting regular participation in religious or spiritual... 2006 Double-blind study n = 36
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Adults with advanced-stage cancer and anxiety 2010 Double-blind, placebo-controlled study n = 12

Citations in the library

Explore topics